Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents

摘要: BACKGROUND Anti-PD-(L)1 blocking agents can induce immune-related adverse events (irAEs), which compromise treatment continuation. Since circulating leukocyte-platelet (PLT) complexes contribute to inflammatory and autoimmune diseases, we aimed analyze the role of these as predictors irAEs in non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1. MATERIALS AND METHODS Twenty-six healthy donors (HD) 87 consecutive advanced NSCLC treated with anti-PD-(L)1 were prospectively included. Percentages leukocyte-PLT analyzed by flow cytometry compared between HD patients. The association presence severity was analyzed. RESULTS had higher percentages complexes. Higher monocytes bound PLT (CD14 + PLT +) observed who received prior therapies while CD4 + T lymphocytes (CD4 + PLT +) correlated platelets counts. CD4 + PLT + high percentage group presented a rate dermatological CD4 + PLT + low showed non-dermatological (p < 0.001). A lower frequency grade ≥ 2 (p < 0.05). Patients CD14 + PLT + high grade ≥ 3 predominantly developed (p < 0.01). CONCLUSIONS Our results suggest that combination CD4 + PLT + and CD14 + PLT + percentages be used predictive biomarker development agents.